Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial

Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversion rates versus GBT alone by Month 6. Limited data...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L., Flume, Patrick A., Thomson, Rachel, Mange, Kevin C., Yuen, Dayton W., Ciesielska, Monika, Morimoto, Kozo, Ruoss, Stephen J., Codecasa, Luigi R., Yim, Jae-Joon, Marras, Theodore K., van Ingen, Jakko, Wallace, Richard J., Brown-Elliott, Barbara A., Coulter, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328368/
https://www.ncbi.nlm.nih.gov/pubmed/33326356
http://dx.doi.org/10.1513/AnnalsATS.202008-925OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328368/
https://www.ncbi.nlm.nih.gov/pubmed/33326356
http://dx.doi.org/10.1513/AnnalsATS.202008-925OC

Ejemplares similares